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Abstract Elastin peptides, such as U-elastin (kE), bind to the
elastin receptor at the cell surface of human dermal ¢broblasts
and stimulate collagenase-1 expression at the gene and protein
levels. Using speci¢c inhibitors and phosphospeci¢c antibodies,
we show here that the binding of elastin peptides to their recep-
tor activates the extracellular signal-regulated kinase (ERK)
pathway; this activation is essential for the induction of pro-
collagenase-1 production. Moreover, protein kinase A (PKA)
and phosphatidylinositol 3-kinase (PI3K) signaling were found
to participate in ERK activation. Concomitantly, we demon-
strate that stimulation by elastin peptides leads to enhanced
DNA binding of activator protein-1 (AP-1). Our data indicate
that the up-regulation of collagenase-1 following treatment of
¢broblasts with elastin peptides results from a cross-talk be-
tween PKA, PI3K and the ERK signaling pathways and that
this regulation is accompanied by activation of AP-1 transcrip-
tion factors. - 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Elastin, a cross-linked polymer of tropoelastin, is found in
the extracellular space of several vertebrates tissues such as
lung, major arteries and skin [1]. Degradation of insoluble
elastin by elastases leads to the production of elastin peptides
[2] which exhibit activities in£uencing cell chemotaxis [3], cell
proliferation [4,5] and gene expression [6]. These e¡ects are
mediated through binding of elastin peptides to their cognate
receptor.
The elastin receptor complex is composed of three distinct
subunits: the elastin-binding protein (EBP), a protective pro-
tein and a neuraminidase [7]. The 67-kDa EBP is an enzymati-
cally inactive, spliced variant of L-galactosidase and possesses
an elastin-binding and a galactolectin site. Occupancy of the
galactolectin site considerably reduces the a⁄nity of the re-
ceptor for elastin leading to the shedding of EBP from the cell
surface [8].
In a previous investigation on human skin ¢broblasts, we
have shown that, following binding to EBP, U-elastin (kE), a
chemical hydrolysate of insoluble elastin, or the elastin syn-
thetic peptide VGVAPG, up-regulated collagenase-1 (matrix
metalloproteinase-1, MMP-1) and stromelysin-1 at the gene
and protein levels [6].
The promoter of MMP-1 contains several regulatory ele-
ments; the activator protein-1 (AP-1) site located at 372 bp
was reported to play an important function in the control of
MMP-1 production [9^11]. We therefore hypothesized that
the stimulation of pro-MMP-1 production observed when hu-
man skin ¢broblasts were cultured in the presence of kE could
involve AP-1 signaling and studied the upstream involvement
of mitogen-activated protein kinases (MAP kinases), as those
enzymes occur upstream of AP-1 signaling by controlling its
activation [12]. As, in the case of MMP-1 production control,
the importance of the MAP/extracellular signal-regulated ki-
nase (MEK)/ERK signaling cascade had been reported several
times [13^15], its possible involvement in kE-induced pro-
MMP-1 production by human skin ¢broblasts was investi-
gated.
Our data demonstrate that activation of the MEK/ERK
signaling pathway is crucial for kE signaling leading to
MMP-1 production. Additionally, we establish that the acti-
vation of this MAP kinase cascade involves synergistic protein
kinase A (PKA) and phosphatidylinositol 3-kinase (PI3K) sig-
naling and that ¢broblasts stimulation by elastin peptides
leads to activation of AP-1 transcription factors.
2. Materials and methods
2.1. Reagents
kE was prepared as described previously [6]. Lactose, alkaline phos-
phatase-conjugated anti-sheep antibody, nitroblue tetrazolium 5-bro-
mo-4-chloro-3-indolyl phosphate alkaline-phosphatase substrate and
isobutylmethylxanthine were purchased from Sigma (Saint Quentin
Fallavier, France).
The sheep anti-human MMP-1 polyclonal antibody, protein kinase
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C (PKC) inhibitor GF109203X, PKA inhibitor H-89 and forskolin
were obtained from Calbiochem (France Biochem, Meudon, France).
The rabbit anti-human double-phosphorylated ERK1/2 (pERK1/2),
horseradish peroxidase-conjugated anti-sheep and anti-rabbit poly-
clonal antibodies, PI3K inhibitor LY294002 and MEK1/2 inhibitor
U0126 were purchased from New England Biolabs (Saint-Quentin-
en-Yvelines, France). The enhanced chemiluminescence substrate so-
lution and [Q-32P]ATP were from Amersham Biosciences (Saclay,
France). Reagents for cell culture were from Life Technologies (Cergy
Pontoise, France). All reagents used for electrophoretic mobility shift
assays were obtained from Promega (Charbonnie'res, France). All
others reagents were from Sigma.
2.2. Cell culture
Human skin ¢broblast strains were established from explants of
human adult skin biopsies obtained from informed healthy volunteers
(age: 21^49 years). Cells were grown as monolayer culture in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum, 200 U/ml penicillin, 50 Wg/ml streptomycin and 2 mM
glutamine in the presence of 5% CO2. Cells at subcultures 2^10
were used. For experiments, ¢broblasts were grown to con£uence in
10% serum-containing medium. Before stimulation, con£uent cells
were incubated for 18 h in DMEM containing 0.5% fetal calf serum,
washed twice with phosphate-bu¡ered saline (PBS) and incubated in
serum-free medium with or without kE, in the presence or absence of
cell signaling e¡ectors. Inhibitors and lactose were added 1 h prior to
kE stimulation.
2.3. Western blot analysis
The protocol used for pro-MMP-1 detection has been described [6].
Brie£y, ¢broblasts were treated with kE for 24 h and the culture
media were harvested and centrifuged (500Ug, 10 min, 4‡C) to re-
move cellular debris. The supernatants were then concentrated using
Microcon YM10 (Millipore, Molsheim, France) and the protein con-
tent resolved by SDS^PAGE under reducing conditions. The mem-
branes were saturated with 5% (w/v) non-fat dry milk, 0.1% (v/v)
Tween-20 in TBS (Tris 50 mM, NaCl 150 mM, pH 7.5), treated
with sheep polyclonal anti-human MMP-1, and then incubated with
alkaline phosphatase-conjugated anti-sheep antibody. Immunocom-
plexes were visualized using nitroblue tetrazolium 5-bromo-4-chloro-
3-indolyl phosphate alkaline phosphatase substrate. The bands were
further quanti¢ed by densitometry using Phosphor Analyst software
(Bio-Rad, Marne-la-Valle¤e, France).
To study ERK1/2 activation, cells were treated with kE and incu-
bations were pursued for 5^60 min. Stimulation was stopped by add-
ing ice-cold PBS containing 50 WM Na3VO4. Cells were then sonicated
in lysis bu¡er (PBS pH 7.4, 0.5% Triton X-100, 80 mM L-glycero-
phosphate, 50 mM EGTA, 15 mM MgCl2, 1 mM Na3VO4, and the
protease inhibitor cocktail from Sigma). Proteins were resolved on
SDS^PAGE under reducing conditions. Protein transfer and blocking
of non-speci¢c binding sites were performed as described above.
Active forms of ERK were visualized using a rabbit anti-human
pERK1/2 primary antibody and a horseradish peroxidase-coupled
anti-rabbit secondary antibody.
2.4. Electrophoretic mobility shift assay
Fibroblasts were incubated with kE for 2^8 h. After removal of the
culture medium, cell layers were scraped, centrifuged, and nuclear
extracts were prepared as described by Staal and co-workers [16].
Binding reactions were established in 20 Wl of binding bu¡er as
previously described [17], using 2 Wg of nuclear extract protein per
assay. Nuclear extracts were incubated for 20 min at room temper-
ature with [Q-32P]ATP end-labelled double-strand AP-1 consensus oli-
gonucleotides, using T4 polynucleotide kinase. The AP-1 oligonucleo-
tide used for the electrophoretic mobility assay was 5P-CGC TTG
ATG AGT CAG CCG GAA-3P.
For competition assays, the nuclear extracts were incubated for
10 min at room temperature with an unlabelled probe before adding
AP-1-labelled probe: AP-1; nuclear factor UB (NF-UB), 5P-AGT TGA
GGG GAC TTT CCC AGG C-3P ; cAMP response-element-binding
protein (CREB), 5P-AGA GAT TGC CTG ACG TCA GAG AGC
TAG-3P. The unlabelled/labelled probe concentration ratio was 100:1.
Samples were electrophoresed through an 8% polyacrylamide gel at
a constant voltage of 180 V and gels were dried before autoradiog-
raphy.
2.5. Radioimmunoassay of cAMP
Cells were incubated for 5 min at 37‡C in DMEM containing 1 mM
isobutylmethylxanthine and activators (forskolin or kE). Reactions
were stopped by addition of 1 M ¢nal concentration of HClO4 fol-
lowed by immersion into an ice bath. The cells were homogenized and
their cAMP content quanti¢ed by a radioimmunological method as
described by Cailla and co-workers [18], except that bound and free
ligand were separated by precipitation of bound ligand with a mixture
of Q-globulin (2.5 mg/ml) in citrate bu¡er (pH 6.2) and polyethylene-
glycol 6000 (20% w/v).
2.6. Statistical analysis
Experiments were performed in triplicate. Results are expressed as
meanVS.E.M. Di¡erences between control means and treated groups
were assessed using Student’s t-test.
3. Results
Consistent with our previous investigation [6], human skin
¢broblasts in culture produced a low level of pro-MMP-1
following 24 h of culture (Fig. 1, lane 1). Depending on the
donor, one or two immunoreactive species having apparent
molecular weight of 57 kDa and 53 kDa were detected corre-
sponding to the glycosylated and non-glycosylated pro-MMP-
1 isoforms respectively. Culturing human skin ¢broblasts in
presence of 50 Wg/ml kE leads to a six-fold increase in pro-
MMP-1 production (Fig. 1, lane 2). When cells were treated
for 24 h in the presence of both 50 Wg/ml kE and 10 WM
U0126, pro-MMP-1 production returned to basal level (Fig.
1, lane 3), while U0126 alone had no e¡ect (Fig. 1, lane 4). It
suggested that kE-mediated MMP-1 over-expression was trig-
gered by the MEK/ERK signaling pathway.
To further investigate these MAP kinase cascade events, we
analyzed ERK phosphorylation by Western blot after kE
stimulation (Fig. 2). When cells were treated without kE,
two faint bands corresponding to the 44 and 42 kDa dou-
ble-phosphorylated forms of ERK-1 and ERK-2 were ob-
served (Fig. 2, lane 1). Supplementation of cell culture me-
dium with kE enhanced the intensity of those bands, up to an
apparent maximum after 30 min of stimulation (Fig. 2, lane
4). In keeping with the relationship between AP-1 transcrip-
tion factors, ERK pathway and transcriptional control of
collagenase-1 gene, we thus investigated AP-1 activation fol-
lowing treatment of cells with kE. The electrophoretic mobil-
ity shift assay experiments presented in Fig. 3 show that a
transcription factor belonging to the AP-1 family is activated
following kE treatment in a time-dependent manner. The
speci¢city of DNA binding was assessed by competition using
unlabelled AP-1, NF-UB and CREB probes (Fig. 3, lanes A,
N, CR respectively). The addition of a 100-fold excess of the
non-radioactive AP-1 probe totally removed the shifted AP-1
signal demonstrating the speci¢city of the binding; on the
contrary, unlabelled CREB and NF-UB sequences competed
partly and totally respectively with the radioactive AP-1
probe.
Upstream regulation of the MEK/ERK cascade typically
involves tyrosine kinases, PKCs and/or cAMP-regulated path-
ways [19^21]. Tyrosine kinases could be excluded since herbi-
mycin A did not interfere with kE-induced expression of
MMP-1 by ¢broblasts [6].
As PKC involvement had been reported in cell chemotaxis
to elastin peptides [22], we investigated the possibility that the
MEK/ERK cascade could be activated by such a kinase.
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GF129203X, a highly speci¢c inhibitor of cPKC, was ine¡ec-
tive at modulating enzyme production (data not shown).
When ¢broblasts were treated with kE (50 Wg/ml) or for-
skolin (1034 M) as a positive control for 5 min, the intra-
cellular cAMP level was increased six- and 19-fold respectively
(Fig. 4A). In parallel, a 24 h chronic forskolin stimulation
(1035 M) of cells signi¢cantly stimulated the production of
pro-MMP-1 by human skin ¢broblasts (Fig. 4B, lane 3). Al-
together, these ¢ndings pointed out that a cAMP-dependent
pathway was probably involved in kE signaling.
PKA has been shown to activate Raf which, in turn, may
trigger the MEK/ERK cascade [21]. In order to check the
involvement of this cAMP-regulated kinase, we used H-89,
a highly speci¢c PKA inhibitor. Inhibition of PKA (Fig. 5,
lane 3) reduced the kE-induced pro-MMP-1 production by
about 50% (Fig. 5, lane 2), while H-89 alone had no e¡ect
(Fig. 5, lane 4). This result clearly indicated that a PKA was
involved in kE-triggered signaling. However, as PKA inhibi-
tion led to partial inhibition of the kE e¡ect on MMP-1 ex-
pression, other signaling pathways leading to MEK/ERK ac-
tivation were suspected to be involved.
Several investigators have recently pointed out that matrix
components could activate PI3K further inducing MEK/ERK
activation [23,24]. We thus tested the in£uence of PI3K inhi-
bition on pro-MMP-1 production (Fig. 6, lane 3). Inhibition
of PI3K by LY294002 in cells treated with kE resulted in an
important reduction (about 60%) of the kE-induced pro-
MMP-1 production, whereas LY294002 alone had no e¡ect
suggesting that PI3K was involved in the signaling events
leading to increased pro-MMP-1 production.
In order to establish a possible cross-talk between the PKA
and PI3K pathways, we analyzed whether their simultaneous
inhibitions exhibited additional e¡ects on ERK phosphoryla-
Fig. 2. E¡ect of kE treatment duration on ERK phosphorylation.
Anti-pERK Western blot analysis. Fibroblasts were stimulated using
kE (50 Wg/ml) for the indicated durations. Cells were then harvested,
cellular extracts prepared and analyzed as described in Section 2.
Fig. 3. Time course of AP-1 activation following treatment of cells
with kE. Electrophoretic mobility shift assay experiments were per-
formed using a [Q-32P]-labelled AP-1 probe on nuclear extracts from
cells incubated for 2, 4 or 8 h in the absence (C) or presence (kE)
of 50 Wg/ml kE. Competition assays were realized with nuclear ex-
tracts from cells treated with kE for 8 h. The radiolabelled AP-1
probe was added after the nuclear proteins had been incubated for
10 min in the presence of an excess of the following cold consensus
sequences: AP-1 (A), NF-UB (N) and CREB (CR).
Fig. 1. Inhibition of the MEK/ERK signaling pathway blocks the e¡ect of kE on pro-MMP-1 production. Upper panel: Western blot detection
of pro-MMP-1. Lower panel: Densitometric analysis of Western blots. Stimulation of cells was achieved using 50 Wg/ml kE. The MEK-speci¢c
inhibitor U0126 was used at 10 WM. *P6 0.05.
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tion. Individual PKA and PI3K inhibitions signi¢cantly re-
duced the level of pERK (Fig. 7, lane 3 and 4 respectively).
Interestingly, when both kinases were simultaneously inhib-
ited (Fig. 7, lane 5), ERK phosphorylation was further re-
duced (Fig. 7, lane 1) suggesting that PKA and PI3K path-
ways were both involved in activation of MEK/ERK cascade.
As we previously described (Fig. 2), intense phosphorylation
of ERK-1 and ERK-2 was noticeable following treatment of
cells with kE for 30 min (Fig. 7, lane 2). ERK phosphoryla-
tion decreased when cells were pretreated with 1 mM lactose
(Fig. 7, lane 6), demonstrating that kE e¡ects on ERK acti-
vation was mediated by EBP.
4. Discussion
MMP expression is regulated by several stimulatory factors
such as phorbol esters, integrin-derived signals, extracellular
matrix macromolecules or fragments, and changes in cell
shape that in£uence a variety of signaling pathways [11]. A
majority of those stimuli lead to activation of c-fos/jun proto-
oncogenes, which heterodimerize and interact with AP-1 sites
in MMP gene promoter as found in collagenase-1 [11]. We
here demonstrated that stimulation of ¢broblasts by elastin
peptides also triggered AP-1 activation. The speci¢city of
DNA binding was demonstrated by the use of a cold AP-1
consensus sequence and con¢rmed by the fact that unlabelled
CREB consensus sequences, which bind AP-1 transcription
factors with low a⁄nity [25], only partially competed with
the radioactive AP-1 probe, while NF-UB probe had no e¡ect.
In most instances, the MEK/ERK MAP kinase pathway is
the main cascade leading to collagenase-1 expression [13^15],
which often involves AP-1 activation [10,11]. Using U0126, a
MEK1/2 inhibitor, at a concentration known to not in£uence
p38 and c-Jun N-terminal MAP kinases [26,27], we were able
to demonstrate the speci¢c implication of that kinase in
MMP-1 expression. On the basis of inhibition of kE-mediated
MMP-1 over-expression following supplementation of ¢bro-
blast culture media with RO-31-8220, we initially proposed
cPKC as a key mediator of protease induction [6]. However,
GF109203X, a more speci¢c cPKC inhibitor, proved to be
ine¡ective in modulating collagenase-1 expression suggesting
that such kinase was not involved in elastin-induced e¡ect.
Fig. 4. E¡ect of kE treatment on the production of cAMP by cultured human skin ¢broblasts and involvement of cAMP-dependent signaling
pathways in the stimulation of pro-MMP-1 production after kE treatment. A: kE treatment increases the intracellular level of cAMP. Radioim-
munoassay of cAMP. F, forskolin used at 1034 M represents the positive control (acute stimulation). Cells were stimulated with kE (50 Wg/ml)
for 5 min. *P6 0.05; **P6 0.01. B: Forskolin (1035 M) reproduces the e¡ect of kE on the production of pro-MMP-1. Densitometric analysis
of anti-MMP-1 Western blots. Cells were grown in the presence of 50 Wg/ml kE for 24 h. F, forskolin was used at 1035 M (chronic stimula-
tion). *P6 0.05; **P6 0.01.
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A rise of cAMP, which has been observed in monocytes
treated with elastin peptides [29], is known to induce ERK
phosphorylation [22,28]. In our cell system, a signi¢cant en-
hancement of cAMP level was observed as early as 5 min
following cell stimulation; furthermore, forskolin, an activa-
tor of adenylylcyclase catalytic subunit, was found to induce
MMP-1 production indicating cAMP was a mediator in the
signaling cascade induced by elastin peptides. Since inhibition
of PKA did not totally block ERK1/2 phosphorylation, we
suspected that another pathway could be involved. Our results
show that PI3K is involved in this signaling as LY294002
inhibited kE-induced ERK phosphorylation. In conclusion,
we show that PI3K and PKA signaling contribute to the acti-
vation of the MEK/ERK cascade induced by treatment of
¢broblasts with elastin peptides.
A number of potential mechanisms by which PI3K can lead
to ERK activation in cells have been described; atypical
PKCs, notably PKCj, are the most likely candidates. Indeed,
the newly synthesized phosphatidylinositol 3,4,5-trisphosphate
recruits phosphoinositide-dependent kinase-1 and PKCj to
the plasma membrane where a combination of lipid binding
and phosphorylation by phosphoinositide-dependent kinase-1
Fig. 5. E¡ect of PKA inhibition on the production of pro-MMP-1 induced by kE treatment. Upper panel: Anti-MMP-1 Western blot. Lower
panel: Densitometric analysis. Stimulation of cells was achieved using 50 Wg/ml kE. The PKA-speci¢c inhibitor H-89 was used at 5 WM.
*P6 0.05; **P6 0.01.
Fig. 6. E¡ect of PI3K inhibition on the production of pro-MMP-1 induced by kE treatment. Upper panel: Anti-MMP-1 Western blot. Lower
panel: Densitometric analysis. Stimulation of cells was achieved using 50 Wg kE/ml. The PI3K-speci¢c inhibitor LY294002 was used at 25 WM.
*P6 0.05; **P6 0.01.
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activates PKCj [30]. PKCj was also shown to phosphorylate
both Raf-1 and MEK directly [31,32]. Another atypical PKC,
PKCN, is also known for its ability to activate the MEK/ERK
pathway via c-Raf [33]. PI3K was found associated with this
aPKC in human hematopoietic cells as well as in platelets [34]
and it seems that PI3K could activate PKCN by an unknown
regulatory mechanism. Finally, PI3K could activate the MEK/
ERK pathway via its intrinsic Ser/Thr kinase activity (PI3K-
protein kinase). Indeed, Bondeva and co-workers [35] have
shown that a PI3K mutant, that had lost its lipid kinase ac-
tivity but retained its protein kinase activity, could activate
ERK. Nevertheless, the mechanism leading to ERK phos-
phorylation remains unknown.
To our knowledge, a cross-talk between PI3K, PKA and
ERK pathways leading to collagenase-1 expression has not
been previously described. Our results demonstrate that inter-
action of ¢broblasts with elastin peptides leads to activation
of transcription factors belonging to the AP-1 family, and
most importantly to PI3K activation. Although our study
focused exclusively on signaling events leading to pro-MMP-
1 production, we feel that the occurrence of PI3K activity
downstream of EBP is particularly important. Indeed, besides
their contribution to the regulation of several genes expres-
sion, these lipid kinases could be connected to many physio-
logical events ([36] and references cited therein) that could be
triggered by elastin peptides, such as cell proliferation [4],
peptide-induced oxidative burst in neutrophils [29] and cell
motility [3]. The involvement of a PI3K in elastin peptide-
triggered processes has now to be considered and extends
the range of elastin peptides activities on cells.
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tively. Cells were stimulated in the presence of kE for 30 min.
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